What are the pathological types and grades of Ductal Carcinoma In Situ (DCIS), such as good, poor, and intermediate, and how do they influence treatment decisions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pathological Classification and Grading of DCIS

DCIS should be classified and reported based on nuclear grade (low, intermediate, or high), presence or absence of necrosis, and architectural pattern, as these features directly influence treatment decisions and risk of local recurrence. 1

Nuclear Grade Classification System

The most clinically relevant classification system for DCIS is based on nuclear grade rather than traditional architectural patterns, as nuclear grade correlates with recurrence risk and treatment outcomes. 1

Three-Tier Nuclear Grading:

  • Low grade (good): Small, uniform nuclei with minimal pleomorphism and rare mitoses 1
  • Intermediate grade: Moderate nuclear pleomorphism with intermediate features between low and high grade 1
  • High grade (poor): Large, pleomorphic nuclei with prominent nucleoli and frequent mitoses 1

High nuclear grade and presence of necrosis (particularly extensive comedonecrosis) are associated with significantly higher risk of early local recurrence following breast conservation therapy. 1

Architectural Patterns

While less predictive of recurrence than nuclear grade, architectural patterns should still be reported as they have clinical relevance: 1

  • Comedo: Characterized by central necrosis
  • Cribriform: Sieve-like pattern with punched-out spaces
  • Micropapillary: Small papillary projections without fibrovascular cores (tends to be more extensive and prone to multiple quadrant involvement) 1
  • Papillary: True papillae with fibrovascular cores
  • Solid: Solid sheets of cells filling ducts

The micropapillary pattern deserves special attention as it tends to be more extensive and prone to involvement of multiple quadrants, independent of nuclear grade. 1

Essential Pathology Report Elements

The pathology report must include these specific features to guide treatment: 1

  • Nuclear grade (low, intermediate, or high) - mandatory
  • Presence or absence of necrosis - mandatory
  • Architectural pattern(s) present
  • Estimated extent (size) of DCIS - critical for treatment planning
  • Surgical margin status - whether DCIS is transected at margins and distance from nearest margin if negative
  • Cell polarization (if applicable) 1

Clinical Implications for Treatment

Nuclear grade and necrosis are the primary pathologic features that determine treatment intensity: 1

  • High-grade DCIS with necrosis: Higher risk of local recurrence; typically requires wider excision margins and radiation therapy is strongly recommended
  • Low-grade DCIS without necrosis: Lower recurrence risk; may be candidates for less aggressive treatment approaches
  • Intermediate-grade DCIS: Requires individualized assessment based on size, margins, and patient factors

Tumors with favorable sizes and grades are associated with increased rates of breast preservation and lower rates of radiotherapy use. 1

Important Caveats

  • No single classification system has been universally adopted, so pathologists must clearly state which grading system is used 1
  • Greatest consistency among pathologists is achieved using nuclear grade-based classification systems rather than architectural pattern-based systems 1
  • No classification system can predict whether local recurrence will be in situ or invasive carcinoma 1
  • Surgical margin assessment is arguably the most important pathologic feature for patients being considered for breast conservation 1
  • Estrogen/progesterone receptors, DNA ploidy, S-phase, and oncogene amplification are not necessary for routine evaluation of DCIS 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is ductal carcinoma?
Is there a familial component to Ductal Carcinoma In Situ (DCIS)?
What is the prognosis for ductal carcinoma (DCIS) of the breast?
What is the recommended adjuvant chemotherapy regimen, follow-up schedule, and surveillance monitoring for a patient with Invasive Ductal Carcinoma (IDC), Stage IIA, Estrogen Receptor positive (ER+), Progesterone Receptor positive (PR+), and Human Epidermal growth factor Receptor 2 (HER2) equivocal Fluorescence In Situ Hybridization (FISH+) positive, status post (S/P) core needle biopsy (CNB) and neoadjuvant chemotherapy?
What is the treatment for carcinoma in situ (cancer in situ)?
What is the difference between using a mucolytic (e.g. acetylcysteine) versus an expectorant (e.g. guaifenesin) in patients with respiratory conditions characterized by thick mucus, such as Chronic Obstructive Pulmonary Disease (COPD) or bronchiectasis?
How does running affect mental resilience in a healthy adult population without severe underlying medical conditions?
What is the best diet for a patient with acute diverticulitis?
Can a patient with sickle cell disease who develops a right atrial (RA) clot and subsegmental pulmonary embolism start on a Direct Oral Anticoagulant (DOAC), such as Apixaban (apixaban), for treatment?
What is the dosage of reslizumab (anti-IL-5 antibody) for a patient with severe asthma?
What is the significance of ER (Estrogen Receptor) and PR (Progesterone Receptor) status, HER2 (Human Epidermal growth factor Receptor 2) status, aneuploidy, diploidy, and p53 in a patient with Ductal Carcinoma In Situ (DCIS)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.